CAR T cells for recurrent glioblastoma that makes GPC3
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a treatment made from your own immune cells, called CAR T cells, which are engineered to find and attack brain tumor cells that have a marker called GPC3. It is for patients whose glioblastoma has come back and who are already scheduled to have another surgery to remove the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with recurrent glioblastoma (a brain tumor that has returned).
- Your tumor must have a protein called GPC3 (the doctor will check a sample from a previous surgery).
- You are able to perform daily activities with some help (Karnofsky score of 60% or higher).
- Your kidneys, liver, and blood counts are within safe ranges (doctor will test these).
- You are not pregnant or nursing, and you agree to use birth control for 3 months after treatment if you are sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T cells—immune cells engineered in the lab to fight a specific brain tumor called ATRT (atypical teratoid rhabdoid tumor). The cells are designed to recognize and attack tumor cells that have a protein called GPC3, and are enhanced with immune-boosting signals to work better.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This trial tests a new type of CAR T-cell therapy that targets a specific protein (EGFRvIII) found on some glioblastoma cells. The treatment is designed to be more effective and potentially safer for people whose brain tumor has come back after previous treatments.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
Hear when a new Glioblastoma Multiforme of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.